Arrowhead Pharmaceuticals reaches 52-week high after FDA designation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 08 Dec 25
Source: Newsfilter
Arrowhead Pharmaceuticals Inc saw a significant price increase of 13.61%, reaching a 52-week high amid positive market conditions.
The company received FDA Breakthrough Therapy designation for its investigational drug plozasiran, aimed at treating severe hypertriglyceridemia. This designation highlights the drug's potential to significantly improve treatment outcomes for patients.
With the completion of Phase 3 clinical trials expected by mid-2026, Arrowhead is well-positioned to meet the urgent market demand for effective therapies, potentially enhancing its competitive edge in the biopharmaceutical sector.
Analyst Views on ARWR
Wall Street analysts forecast ARWR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 75.50 USD with a low forecast of 35.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 65.580
Low
35.00
Averages
75.50
High
100.00
Current: 65.580
Low
35.00
Averages
75.50
High
100.00
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
